<DOC>
	<DOCNO>NCT00998309</DOCNO>
	<brief_summary>To collect efficacy safety information Zithromax-SR related appropriate use daily practice .</brief_summary>
	<brief_title>Zithromax-SR 2g , Special Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All patient investigator prescribes first Azithromycin SR register within 14 day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Sexually Transmitted Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Male female subject diagnose skin soft tissue infection , sexuallytransmitted infection , infection oral . Subjects must prior experience Azithromycin SR . Patients administer Azithromycin SR .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>skin infection</keyword>
	<keyword>soft tissue infection</keyword>
	<keyword>sexually-transmitted infection</keyword>
	<keyword>infection oral</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>